King's Mill Hospital
Mansfield Road
Sutton in Ashfield
Nottinghamshire
NG17 4JL

Tel: 01623 622515
Join today: www.sfh-tr.nhs.uk

Direct Line: 01623 672232
Our Ref: 1278
E-mail: sfh-tr.foi.requests@nhs.net

7th April 2026

[redacted]

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: FOI Request: Acute Myeloid Leukaemia (AML) Patients 2025

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold some of the information you have requested. A response to each part of your request is provided below. Please accept our sincere apologies for the delay.

FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details
1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months Jan-Dec 2025? • Of these patients how many are refractory/relapsed R/R)? • How many of the R/R patients were FLT3 positive?	14 patients R/R status and FLT are not held in an electronic reportable format.			
2. How many patients have been treated for AML in the latest 12 months Jan - Dec 2025 with the following treatments • Venetoclax with azacitidine • Midostaurin • Quizartinib • Gemtuzumab • Ivosidenib with azacitidine • Liposomal cytarabine–daunorubicin • Oral azacitidine • Gilteritinib • Palliative care • Enrolled in a clinical trial	• Venetoclax with azacitidine - 3 Patients • Midostaurin - 0 Patients • Quizartinib - 0 Patients • Gemtuzumab - 0 Patients • Ivosidenib with azacitidine - 0 Patients • Liposomal cytarabine–daunorubicin - 0 Patients • Oral azacitidine - 0 Patients • Gilteritinib - 1 Patients • Palliative care - 3 Patients • Enrolled in a clinical trial - 6 Patients We have only issued Ventoclax tablets and Azacitidine injections in this time period. We are unable to positively identify if a patient was treated with both.			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

3. How many relapsed/refractory patients have been treated for AML in the last 12 months Jan - Dec 2025 with the following treatments This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use). • Venetoclax with azacitidine • Midostaurin • Quizartinib • Gemtuzumab; • Ivosidenib with azacitidine • Liposomal cytarabine–daunorubicin • Oral azacitidine • Gilteritinib • Palliative care • Enrolled in a clinical trial	This information is not recorded in an electronic reportable format.			
4. Of your AML patient how many were tested as below in the last 12 months • Received an FLT3 mutation test when they were diagnosed • Received an FLT3 mutation test when their disease relapsed • Received an FLT3 mutation test when their disease became refractory	This Information is not captured in an electronic reportable format. A number of these patients are transferred to other providers. Under Section 16 of the Act, we have a duty to provide advice and assistance. Please contact Nottingham University			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

	Hospitals NHS Trust nuhnt.dutyin@nhs.net who may hold this information.			

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net

I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: https://ico.org.uk/your-data-matters/official-information/.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email casework@ico.org.uk.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email sfh-tr.foi.requests@nhs.net.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the Open Government Licence (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.